GlassScriptPhysician profile
Victor M Plavner
NPI 1104818004
$16,135.99
in general payments reported to CMS, 2019-2025
66 companies · $2,662 in 2025
The $2,662 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $1,591 · 2021: $2,082 · 2022: $1,575 · 2023: $2,724 · 2024: $3,924 · 2025: $2,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,830 · Consulting Fee: $2,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,830.06 |
| Consulting Fee | $2,480.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,589.32 | 2020-2024 | |
| Abbvie INC. | $2,447.25 | 2019-2025 | |
| Novo Nordisk INC | $2,176.55 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,242.72 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $1,021.50 | 2019-2025 | |
| Lilly USA, LLC | $692.68 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $594.81 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Allergan, INC. | $411.81 | 2019-2020 | |
| Amgen INC. | $382.33 | 2019-2024 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $367.39 | 2019-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $315.26 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.04 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.49 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $236.71 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Amarin Pharma, INC. | $218.54 | 2019-2021 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Plavner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.